Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (June 2021)
28 slides from Devonian Health's investor presentation, June 2021
Slide 1: Global Leader in Prescription Botanical Drug Discovery and Research & Development
Global Leader in Prescription Botanical Drug Discovery and Research & Development June 2021 TSXv: GSD
Slide 2: Cautionary Statements
Cautionary Statements Certain statements contained in this document constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) pursuant to the Applicable Securities Regulations. All statements, other than statements of historical fact, containe
Slide 3: Devonian Health Group – a snapshot
Devonian Health Group – a snapshot A Leader in the Discovery, Research & Development (R&D) of Botanical Drugs / Pharmaceuticals (prescriptions) following US-FDA, Germany-BfArM, and Health Canada Regulations Principal Asset Thykamine™ ready to embark on Phase 3 trial for mid-to-moderate Adult Atopic
Slide 4: Thykamine: Journey from Farm to Pharm
Thykamine™ Journey from Farm to Pharm™ Farm toPharm™
Slide 5: Unique Proprietary Technology protected by Patents and Industrial secrets
Unique Proprietary Technology protected by Patents and Industrial secrets SOURCING EXTRACTION DEVELOPMENT BOTANICALS of ACTIVE BOTANICAL INGREDIENTS (ABI) with SUPREX™ of RX BOTANICAL DRUGS (Botanical complexes) And COSMECEUTICALS Organic Baby Spinach SUPREX™ Process Thykamine™ Pharma-grade Supply C
Slide 6: R&D Program set for Phase trial in preparation for first entry into Market
R&D Program set for Phase 3 trial in preparation for first entry into Market DRUG DEVELOPMENT PIPELINE WITHIN A PRODUCT DERMATOLOGY Indication Preclinical Phase 1 Phase 2 Phase 3 Atopic Dermatitis (Adult - Topical) Atopic Dermatitis (Pediatric - Topical) Hand and Foot Syndrome associated to Chemothe
Slide 7: Pipeline development within a product
Pipeline development within a product MECHANISM OF ACTION IMPACTING SEVERAL METABOLIC TARGETS ALLOWING FOR MULTIPLE INDICATIONS Global anti-inflammatory market surpassing $117 billion by 2022 AUTO-IMMUNE DISEASES OTHER INFLAMMATORY DISEASES DERMATOLOGY DERMATOLOGY Atopic Dermatitis (AD) Radiodermati
Slide 8: Strong Leadership and Advisory Boards
Strong Leadership and Advisory Boards MANAGEMENT André P. Boulet, PhD Sybil Dahan, BSc. Tarique Saiyed, FCA Colette Laurin CPA, CA Mostafa Akbarieh, PhD Nathalie Boucher, PhD CEO & CSO President, Altius Healthcare Director Interim CFO V.P. Regulatory Affairs Director Research and IP __________ _____
Slide 9: Botanical Drug regulations - less costly and condensed R&D program
Botanical Drug regulations - less costly and condensed R&D program allowing for quick-to-market NEXT WAVE IN PHARMACEUTICALS BENEFITS OVER CHEMICALLY SYNTHESISED DRUGS ▪ Specific FDA regulations: Botanical Drug ▪ Faster preclinical development, and as robust Regulations clinical program as for tradi
Slide 10: Licensed State-of-the-Art Pharmaceutical-grade (cGMP) Production Facility
Licensed State-of-the-Art Pharmaceutical-grade (cGMP) Production Facility PHARMACEUTICAL GRADE INTELLECTUAL PROPERTY • Full scale facility with custom designed equipment ✓ Over 44 patents issued or pending • Full traceability « from seed to pill » ✓ 7 Trademarks ✓ Trade secrets related to extraction
Slide 11: Devonian's Target Therapeutic Areas and Indications in high value markets
Devonian’s Target Therapeutic Areas and Indications in high value markets THERAPEUTIC INDICATIONS GLOBAL MARKET (Forecasted by 2025) Atopic Dermatitis (Eczema) US$21.8Bn1 15-30% of children Leadership Position Opportunity Ulcerative Colitis (Inflammatory Bowel Disease) US$10Bn4 0.2% of population Ra
Slide 12: Thykamine - first-line treatment for Mild-to-Moderate Adult Atopic Dermatitis
Thykamine™ - first-line treatment for Mild-to-Moderate Adult Atopic Dermatitis • 192 drugs in various stages of R&D at the end of December 2020 (1) • 14 drugs in phase 3 clinical trials • 68 drugs in phase 2 clinical trials • 3 currently under investigation targeting Mild-to-Moderate Adult Atopic De
Slide 13: Thykamine - Only drug in trial targeting pediatric Atopic Dermatitis
Thykamine™ - Only drug in trial stage targeting Atopic Dermatitis Pediatric population of 3 months and older • Out of 192 drugs in various stages of R&D(2) only 3 targeting the Atopic Dermatitis Pediatric population (1) • Thykamine™ only one targeting the age of 3 months and older Products RVT-501 A
Slide 14: Unmet medical need remains in Mild-to-Moderate Atopic Dermatitis
Unmet medical need remains in Mild-to- Moderate Atopic Dermatitis MARKETED PRODUCTS • Topical treatment is the mainstay of treatment of mild-to-moderate AD, highly genericized • Emollients and sedative anti-histamines needs to be used conjunctively with current therapies • Major side effects or warn
Slide 15: Thykamine: Novel Anti-Inflammatory Drug with multiple indications
Thykamine™ Novel Anti-Inflammatory Drug with multiple indications Farm toPharm™
Slide 16: Positive impact on Ulcerative Colitis symptoms in Phase 2 trial
Positive impact on Ulcerative Colitis symptoms (UC) in Phase 2 (proof of concept) trial Clinical Symptoms (1) Rectal Bleeding – Modified Mayo Sub-Score 0 Patients with left- Placebo Day 7 Day 14 Day 21 -0.2 sided Mid-to- (n=5) Mean Change from Baseline in Moderate Ulcerative Colitis -0.4 Rectal Blee
Slide 17: Outstanding Anti-Inflammatory effect at day 21 in UC patients
Outstanding Anti-Inflammatory effect at day 21 in UC patients Biomarkers 60 40 20 0 % -20 -40 -60 * Placebo Thykamine™ 250 mg/day -80 -100 * * P ˂ 0.05 (1) A 2-Week Exploratory Randomized, Double-Blind, Parallel- Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Cl
Slide 18: Primary Endpoint met in Adult Atopic Dermatitis Phase 2 trial
Primary Endpoint met in Adult Atopic Dermatitis (AD) Phase 2 trial – setting stage for Phase 3 Change in IGA from Baseline 0 Adult Patients Placebo Day 7 (n=40) Day 14 Day 21 Day 29 with Mid-to- Moderate -0.2 Atopic Dermatitis 0.05% Day 7 Day 14 Day 21 Day 29 (n=44) -0.4 Randomization 0.1% -0.6 * Da
Slide 19: Efficacy reached prior to Endpoint timeline – faster relief of symptoms
Efficacy reached prior to Endpoint timeline – faster relief of symptoms Primary Endpoint by Follow-up Day and Treatment Group 35.0% 30.0% * 25.0% * 20.0% * 15.0% * 10.0% 5.0% 0.0% * p< 0.05 Day 7 Day 14 Day 21 Day 29 Placebo Vehicle Cream Thykamine Cream 0.05% Thykamine Cream 0.10% Thykamine Cream 0
Slide 20: Secondary Endpoints met solidifying readiness to move to Phase 3 trials
Secondary Endpoints met solidifying readiness to move to Phase 3 trials Change in BSA from Baseline Low incidence of Adverse Events 1 0.5 0 -0.5 -1 -1.5 * -2 * * -2.5 ** -3 ** -3.5 ** • Itching (pruritis) Day 0 Day 7 Day 14 Day 21 Day 29 • Patient self-assessment score (POEM) Axis Title * p ˂ .05 **
Slide 21: Efficacy rate similar to drugs derived from chemical synthesis
Efficacy rate similar to drugs derived from chemical synthesis Competitive Landscape vs New Chemical Entities DRUG MECANISM OF ACTION CLINICAL PATIENT % Patients reaching DEVELOPMENT PHASE POPULATION Primary Endpoint (p < 0.05) Thykamine1 Immunomodulator II Adults 30.8% * crisaborole 2 Pospohodieste
Slide 22: Efficacy and safety of Thykamine demonstrated in distinct therapeutic indications
Efficacy and safety of Thykamine™ demonstrated in 2 distinct therapeutic indications SOLIDIFYING PROOF OF CONCEPT ATOPIC DERMATITIS ULCERATIVE COLITIS • Fast onset of action – Primary Endpoint met earlier • Fast onset of action • Impact on symptoms: Primary and Secondary Efficacy • Impact on symptom
Slide 23: All in place to go from Farm to Pharm
All in place to go from Farm to Pharm™ Unique Extraction Thykamine™ Thykamine™ Ready for Phase 3 Global DIN and and Processing outstanding anti- Efficacy success Setting stage for Reimbursement methodology inflammatory rates in AD Global Market status similar to backed by effect with similar to entr
Slide 24: Unlocking Multi-Billion Dollar Markets
Unlocking Multi-Billion Dollar Markets Farm toPharm™
Slide 25: Maximizing one high value market
Maximizing one high value market THERAPEUTIC INDICATIONS GLOBAL MARKET (Forecasted by 2025) Atopic Dermatitis (Eczema) 15-30% of children US$19Bn1 Leadership Position Opportunity • Global AD market valued at $10.4B in 2020, expected to double in 5 years1 • Genericized market consisting of topical co
Slide 26: Stock and Financial Information
Stock and Financial Information1 CAPITAL STRUCTURE Subordinate voting shares 73,494,165 Multiple voting shares 19,966,523 TOTAL OUTSTANDING SHARES 93,460,688 Warrants 9,740,623 Stock Options 7,090,000 FULLY DILUTED SHARE CAPITAL 110,291,311 $15.0 Insider Ownership 30% LONG-TERM DEBTS ($ Mil) Secured
Slide 27: All the right ingredients for success
All the right ingredients for success Unique position Faster & Thykamine™ Near-term value Management North American economical outstanding creation solid track record botanical preclinical anti- opportunities of execution pharmaceutical development inflammatory with large drug effect with Pharma dev
Slide 28: Thank you
Y. % 4 Thank you DEVONIAN: TSXv: GSD
Devonian Health Group — Investor Presentation (June 2021) on 6ix